Oncology
Immuno Oncology
Anti-Virus
Disease Modeling
Cosmetics
Toxicity
Spatial Biology
Technology Service
Cancer Organoid
Research Service
Others
Summary: Vertex Pharmaceuticals and CRISPR Therapeutics have received FDA approval for Casgevy, a CRISPR-Cas9 based therapy for beta thalassemia. This treatment is used to reduce transfusion dependence in beta thalassemia patients and is the first CRISPR-based therapy approved in the US, having been previously approved for sickle cell disease last month.
Summary: Novartis has acquired Deciphera Pharmaceuticals for $2.4 billion, securing rights to the FDA and European-approved cancer drug Qinlock. This deal marks significant progress in adult gastrointestinal tumor treatment and is considered a crucial acquisition strengthening Novartis’s oncology portfolio.
Summary: Bicara Therapeutics raised $315 million through the third-largest biotech IPO of 2024. The company is focusing on developing immuno-oncology therapies, and this funding will support clinical research for their immune-based cancer treatments. This deal is considered significant, symbolizing the recovery of the biotech IPO market.
Summary: Zenas BioPharma raised funds through a $225 million IPO to develop immunotherapies. The company is focusing on treatments for autoimmune diseases, and plans to expand investments in ongoing clinical research and new drug development through this IPO. It is notably one of the cases gaining attention alongside the upward trend in the IPO market.
Summary: Generate Biomedicines has signed a $1 billion deal with Novartis to develop an AI-based drug discovery platform. This collaboration focuses on using artificial intelligence for drug discovery and the development of antibody-drug conjugate (ADC) therapies. It is considered a significant milestone that will promote the convergence of AI and biology.
@ 2024 . All rights reserved
@ 2024 . All rights reserved
